Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

About this Study

This study will investigate whether a new experimental treatment, DFP‑10917, will be an effective and safe treatment option for patients with relapsed/refractory acute myelogenous leukemia (AML).  This is a “randomized” study. If it is determined during screening that you are eligible for the study, you will be “randomized” by a computer to receive either DFP-10917 (the experimental group) or standard treatment (control group) by chance. Neither you nor your study doctor can choose the group you will be in.  

Sponsor Protocol ID:D18-11141
IRB Number:2022-115
Actively Enrolling
Phase 3
November 20, 2023
Eligibility Criteria
18 years old
Both Male and Female
Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Principal Investigator:Stephanie Elkins
How to participate in our Clinical Trials